Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: Association with liver fibrosis

Basit Öğe Kaydı
dc.contributor.authorColak, Yasar
dc.contributor.authorSenates, Ebubekir
dc.contributor.authorCoskunpinar, Ender
dc.contributor.authorOltulu, Yasemin Musteri
dc.contributor.authorZemheri, Ebru
dc.contributor.authorOzturk, Oguzhan
dc.contributor.authorDoganay, Levent
dc.date.accessioned2024-04-24T17:12:07Z
dc.date.available2024-04-24T17:12:07Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim: In this study, we aimed to investigate the relationship between the histological fibrosis stage of nonalcoholic fatty liver disease (NAFLD) and serum connective tissue growth factor (CTGF) to determine the usefulness of this relationship in clinical practice. Methods: Serum samples were collected from 51 patients with biopsy-proven NAFLD and 28 healthy controls, and serum levels of CTGF were assayed by ELISA. Results: Levels of CTGF were significantly higher in patients with NAFLD compared with controls (P = 0.001). The serum CTGF levels were significantly increased, that correlated with histological fibrosis stage, in patients with NAFLD [in patients with no fibrosis (stage 0) 308.2 +/- 142.9, with mild fibrosis (stage 1-2) 519.9 +/- 375.2 and with advanced fibrosis (stage 3-4) 1353.2 +/- 610 ng/l, P < 0.001]. Also serum level of CTGF was found as an independent predictor of histological fibrosis stage in patients with NAFLD (beta = 0.662, t = 5.6, P < 0.001). The area under the ROC curve was estimated 0.931 to separate patients with severe fibrosis from patients with other fibrotic stages. Conclusion: Serum levels of CTGF may be a clinical utility for distinguishing NAFLD patients with and without advanced fibrosis.en_US
dc.identifier.doi10.1155/2012/283726
dc.identifier.endpage83en_US
dc.identifier.issn0278-0240
dc.identifier.issn1875-8630
dc.identifier.issue2en_US
dc.identifier.pmid22846210
dc.identifier.scopus2-s2.0-84864420876
dc.identifier.scopusqualityQ2
dc.identifier.startpage77en_US
dc.identifier.urihttps://doi.org/10.1155/2012/283726
dc.identifier.urihttps://hdl.handle.net/11468/17858
dc.identifier.volume33en_US
dc.identifier.wosWOS:000306651000003
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherHindawi Ltden_US
dc.relation.ispartofDisease Markers
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNonalcoholic Fatty Liver Disease (Nafld)en_US
dc.subjectNonalcoholic Steatohepatitis (Nash)en_US
dc.subjectConnective Tissue Growth Factor (Ctgf)en_US
dc.subjectFibrosisen_US
dc.titleConcentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: Association with liver fibrosisen_US
dc.titleConcentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: Association with liver fibrosis
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu